1. Generics in Cardiovascular Diseases Market to 2018 - Loss of
Lipitor Market Exclusivities and Impending Patent Expirations
of Plavix to Drive Generic Substitution
Report Details:
Published:May 2012
No. of Pages: 129
Price: Single User License – US$3500
Corporate User License – US$10500
Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and
Impending Patent Expirations of Plavix to Drive Generic Substitution
Summary
GBI Research, the leading business intelligence provider, has released its latest research
“Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and
Impending Patent Expirations of Plavix to Drive Generic Substitution”. The report provides in-depth
analysis of drivers and barriers that impact the global cardiovascular disorders market. The report
analyzes the generics market for cardiovascular disorders in the US, the top five countries in
Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns are
forecast until 2018 for the key geographies as well as the leading therapeutic segments.
Furthermore, the report provides competitive benchmarking for the leading companies and
analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GBI Research’s team of industry experts.
The global generics market cardiovascular drugs is expected to grow rapidly due to the growing
dyslipdemia, thrombosis and hypertension populations in the developed countries, as well as
patent expiries of major blockbusters such as Lipitor (atorvastatin), Plavix (clopidigrel) and Diovan
(valsartan). The patent expiries of these blockbuster drugs will trigger generic competition in the
cardiovascular therapeutics market, making it more competitive.
In 2010, the generics market for cardiovascular drugs was estimated at $20.5 billion, indicating a
year on year decline of 0.9% from 2004-2010. Patent expiries of the leading
antiplatelets/antithrombotics such as Plavix (clopidigrel) and Lovenox (enoxaparin) and lipid

2. lowering blockbuster Lipitor in 2010-2012, resulting in uptake of generics, is expected to cause the
market to increase significantly from 2010 to 2018.
Scope
- Annualized market data for the generics in cardiovascular disorders market from 2004 to 2010,
forecast forward to 2018.
- Analysis of the leading therapeutic segments, including pulmonary arterial hypertension,
thrombosis, dyslipidemia, hypertension, coronary artery disease, and Angina Pectoris.
- Analysis of the generics in cardiovascular disorders market in the leading geographies of the
world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the generics in cardiovascular disorders market, including market size,
annual cost of treatment and treatment usage pattern.
- Key drivers and barriers that have a significant impact on the generics market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading generic companies. The key companies studied in this
report are
- Key M&A activities, licensing agreements that have taken place from 2004 to 2011 in the global
cardiovascular disorders market.
Reasons to buy
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their
portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets
poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class
molecules which are safer and more efficacious.
Get your copy of this report @
http://www.reportsnreports.com/reports/144406-generics-in-cardiovascular-diseases-market-to-2018-loss-of-lipitor-
market-exclusivities-and-impending-patent-expirations-of-plavix-to-drive-generic-substitution.html
Major points covered in Table of Contents of this report include
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10
2 Generics in Cardiovascular Diseases Market to 2018 – Introduction 12
3 Generics in Cardiovascular Diseases Market to 2018 - Global Market Overview 13
3.1 Introduction 13

3. 3.1.1 Antidyslipidemics 13
3.1.2 Anti-Hypertensives 15
3.1.3 Rise in Generics in CVD Market 15
3.2 Revenue 16
3.3 Annual Cost of Therapy 18
3.4 Treatment Usage Patterns 19
3.4.1 Disease population 20
3.4.2 Treatment Seeking Population 20
3.4.3 Diagnosed Population 20
3.4.4 Prescription Population 20
4 Generics in Cardiovascular Disease Market to 2018 - Geographical Landscape 21
4.1 The US 21
4.1.1 Revenue 21
4.1.2 Annual Cost of Therapy 22
4.1.3 Treatment Usage Patterns 24
4.2 Top Five Countries of Europe 26
4.2.1 Revenue 26
4.2.2 Annual Cost of Therapy 27
4.2.3 Treatment Usage Patterns 28
4.3 Japan 30
4.3.1 Revenue 30
4.3.2 Annual Cost of Therapy 31
4.3.3 Treatment Usage Patterns 32
5 Generics in Cardiovascular Diseases Market to 2018- Therapeutic Landscape 34
5.1 Thrombosis 34
5.1.1 Introduction 34
5.1.2 Revenue 35
5.1.3 Annual Cost of Therapy 36
5.1.4 Treatment Flow Algorithm 37
5.1.5 Treatment Usage Pattern 38
5.1.6 Drivers and Restraints 40
5.1.7 Drivers 40
5.1.8 Restraints 40
5.2 Pulmonary Arterial Hypertension 41
5.2.1 Introduction 41
5.2.2 Revenue 43
5.2.3 Annual Cost of Therapy 44
5.2.4 Treatment Usage Patterns 46
5.2.5 Treatment Flow Algorithm 48
5.2.6 Drivers and Restraints 48
5.2.7 Drivers 49

4. 5.2.8 Restraints 49
5.3 Hypertension 50
5.3.1 Introduction 50
5.3.2 Revenue 51
5.3.3 Annual Cost of Therapy 52
5.3.4 Treatment Flow Algorithm for Hypertension 53
5.3.5 Treatment Usage Patterns 54
5.3.6 Drivers and Restraints 56
5.3.7 Drivers 56
5.3.8 Restraints 56
5.4 Dyslipidemia Market 57
5.4.1 Introduction 57
5.4.2 Revenue 57
5.4.3 Annual Cost of Therapy 59
5.4.4 Treatment Flow Algorithm 60
5.4.5 Treatment Usage Patterns 61
5.4.6 Drivers and Restraints 62
5.4.7 Drivers 63
5.4.8 Restraints 63
5.5 Coronary Artery Disease 64
5.5.1 Introduction 64
5.5.2 Revenue 64
5.5.3 Annual Cost of Therapy 66
5.5.4 Treatment Usage Patterns 67
5.5.5 Drivers and Restraints 69
5.5.6 Drivers 69
5.5.7 Restraints Market 70
5.6 Angina Pectoris Market 70
5.6.1 Introduction 70
5.6.2 Revenue 71
5.6.3 Cost of Therapy 72
5.6.4 Treatment Flow Algorithm 73
5.6.5 Treatment Usage Patterns 74
5.6.6 Drivers and Restraints 75
5.6.7 Drivers for the Angina Pectoris Market 76
5.6.8 Restraints for the Angina Pectoris Market 76
6 Generics in Cardiovascular Diseases Market to 2018 - Product Pipeline Analysis 77
6.1 Introduction 77
6.1.1 Research and Development Pipeline – Pulmonary Arterial Hypertension 78
6.1.2 Research and Development Pipeline – Dyslipidemia 81
6.1.3 Research and Development Pipeline – Coronary Artery Disease 87

5. 6.1.4 Research and Development Pipeline – Angina Pectoris 89
6.1.5 Research and Development Pipeline – Thrombosis 89
6.1.6 Research and Development Pipeline – Hypertension 92
7 Generics in Cardiovascular Diseases Market to 2018 - Most Promising Pipeline Molecules 99
7.1 Eliquis 99
7.1.1 Introduction 99
7.1.2 Mechanism of Action 99
7.2 RG1658 (Dalcetrapib, JTT-705, RO4607381) 99
7.2.1 Introduction 99
7.2.2 Mechanism of Action 99
7.2.3 Clinical Trial Management 1 99
7.3 MK-0524A (Cordaptive, niacin + laropiprant) 100
7.3.1 Introduction 100
7.3.2 Mechanism of Action 100
7.3.3 Clinical Trial Management 2 100
7.4 AMR101 (LAX-101, Miraxion) 101
7.4.1 Introduction 101
7.4.2 Mechanism of Action 101
7.4.3 Clinical Trial Management 3 101
8 Generics in Cardiovascular Diseases Market to 2018 – Competitive Landscape 102
8.1 Teva Pharma 102
8.2 Sandoz 102
8.3 Actavis 102
8.4 Apotex 102
8.5 Watson Pharmaceuticals 103
8.5.1 Watson Launches First Generic Lipitor (atorvastatin) 103
8.6 Mylan 103
9 Generics in Cardiovascular Diseases Market to 2018 – Strategic Consolidations 104
9.1 Merger and Acquisition Deals (2004-2011) 104
9.1.1 Deals by Year 106
9.1.2 M&A Deals by Region 107
9.1.3 M&A Deals by Value 108
9.1.4 Deal Summary of Top 10 M&A Deals by Value 109
9.2 Licensing Deals 111
9.2.1 Deals by Indication 113
9.2.2 Deals by Geography 114
9.2.3 Deals by Year 115
9.2.4 Deal Summary of Top Five Licensing Deals by Value 116
9.3 Co-development Deals 117
9.3.1 Deals by Indication 117
9.3.2 Deals by Geography 118

6. 9.3.3 Deals by Year 119
9.3.4 Deal Summary of Top Five Co-development Deals by Value 120
10 Generics in Cardiovascular Diseases Market to 2018 - Appendix 122
10.1 Market Definitions 122
10.2 Abbreviations 122
10.3 Sources 123
10.4 Research Methodology 124
10.4.1 Coverage 124
10.4.2 Secondary Research 125
10.4.3 Primary Research 125
10.4.4 The report consists of the following four major sections 125
10.4.5 Therapeutic Landscape 126
10.4.6 Forecasting Model for Therapeutic Areas 128
10.4.7 Geographical Landscape 129
10.4.8 Pipeline Analysis 129
10.4.9 Competitive Landscape 129
10.4.10 Expert Panel Validation 129
10.5 Contact Us 129
10.6 Disclaimer 129
1.1 List of Tables
Table 1: Generics in Cardiovascular Diseases Market, Patent Expiries of Leading Cardiovascular
Drugs, 2011 14
Table 2: Generics in Cardiovascular Diseases Market, Global, Revenue ($bn), 2004–2010 17
Table 3: Generics in Cardiovascular Diseases Market, Global, Revenue Forecasts ($bn),
2010–2018 17
Table 4: Generics in Cardiovascular Diseases Market, Global, Annual Cost of Therapy($),
2004–2010 18
Table 5: Generics in Cardiovascular Diseases Market, Global, Annual Cost of Therapy($),
2010–2018 18
Table 6: Generics in Cardiovascular Diseases Market, Global, Treatment Usage Patterns (million),
2004–2010 19
Table 7: Generics in Cardiovascular Diseases Market, Global, Treatment Usage Patterns (million),
2010–2018 20
Table 8: Generics in Cardiovascular Diseases Market, The US, Revenue ($bn), 2004–2010 21
Table 9: Generics in Cardiovascular Diseases Market, The US, Revenue Forecasts ($bn),
2010–2018 22
Table 10: Generics in Cardiovascular Diseases Market, The US, Annual Cost of Therapy($),
2004–2010 22
Table 11: Generics in Cardiovascular Diseases Market, The US, Annual Cost of Therapy($),
2010–2018 23

7. Table 12: Generics in Cardiovascular Diseases Market, The US, Treatment Usage Patterns
(million), 2004–2010 24
Table 13: Generics in Cardiovascular Diseases Market, The US, Treatment Usage Patterns
(million), 2010–2018 24
Table 14: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Revenue
($bn), 2004–2010 26
Table 15: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Revenue
Forecasts ($bn), 2010–2018 26
Table 16: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Annual
Cost of Therapy($), 2004–2010 27
Table 17: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Annual
Cost of Therapy ($), 2010–2018 27
Table 18: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Treatment
Usage Patterns (million), 2004–2010 28
Table 19: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Treatment
Usage Patterns (million), 2010–2018 28
Table 20: Generics in Cardiovascular Diseases Market, Japan, Revenue ($bn), 2004–2010 30
Table 21: Generics in Cardiovascular Diseases Market, Japan, Revenue Forecasts ($bn),
2010–2018 30
Table 22: Generics in Cardiovascular Diseases Market, Japan, Annual Cost of Therapy ($),
2004–2010 31
Table 23: Generics in Cardiovascular Diseases Market, Japan, Annual Cost of Therapy ($),
2010–2018 31
Table 24: Generics in Cardiovascular Diseases Market, Japan, Treatment Usage Patterns
(million), 2004–2010 32
Table 25: Generics in Cardiovascular Diseases Market, Japan, Treatment Usage Patterns
(million), 2010–2018 32
Table 26: Generics in Thrombosis Market, Global, Revenue ($m), 2004–2010 35
Table 27: Generics in Thrombosis Market, Global, Revenue Forecasts ($m), 2010–2018 35
Table 28: Generics in Thrombosis Market, Global, Annual Cost of Therapy ($), 2004–2010 37
Table 29: Generics in Thrombosis Market, Global, Annual Cost of Therapy ($), 2010–2018 37
Table 30: Generics in Thrombosis Market, Global, Treatment Usage Pattern (million), 2004–2010
38
Table 31: Generics in Thrombosis Market, Global, Treatment Usage Pattern (million), 2010–2018
38
Table 32: Generics in Pulmonary Arterial Hypertension Market, Global Revenue ($m), 2004–2010
43
Table 33: Generics in Pulmonary Arterial Hypertension Market, Global, Revenue Forecasts ($m),
2010–2018 44
Table 34: Generics in Pulmonary Arterial Hypertension Market, Global, Annual Cost of Therapy
($), 2004–2010 45

8. Table 35: Generics in Pulmonary Arterial Hypertension Market, Global, Annual Cost of Therapy
($), 2010–2018 45
Table 36: Generics in Pulmonary Arterial Hypertension Market, Global, Treatment Usage Patterns,
(‘000), 2004–2010 46
Table 37: Generics in Pulmonary Arterial Hypertension Market, Global, Treatment Usage Patterns,
(‘000), 2010–2018 46
Table 38: Generics in Hypertension Market, Global, Revenue ($bn), 2004–2010 51
Table 39: Generics in Hypertension Market, Global, Revenue Forecasts ($bn), 2010–2018 51
Table 40: Generics in Hypertension Market, Global, Annual Cost of Therapy ($), 2004–2010 52
Table 41: Generics in Hypertension Market, Global, Annual Cost of Therapy ($), 2010–2018 53
Table 42: Generics in Hypertension Market, Global, Treatment Usage Pattern (million), 2004–2010
54
Table 43: Generics in Hypertension Market, Global, Treatment Usage Pattern (million), 2010–2018
54
Table 44: Generics in Dyslipidemia Market, Global, Revenue ($bn), 2004–2010 57
Table 45: Generics in Dyslipidemia Market, Global, Revenue Forecasts ($bn), 2010–2018 58
Table 46: Generics in Dyslipidemia Market, Global, Annual Cost of Therapy ($), 2004–2010 59
Table 47: Generics in Dyslipidemia Market, Global, Annual Cost of Therapy ($), 2010–2018 59
Table 48: Generics in Dyslipidemia Market, Global, Treatment Usage Pattern (million), 2004–2010
61
Table 49: Generics in Dyslipidemia Market, Global, Treatment Usage Pattern (million), 2010–2018
61
Table 50: Generics in Coronary Artery Disease Market, Global, Revenue ($m), 2004–2010 65
Table 51: Generics in Coronary Artery Disease Market, Global, Revenue Forecasts ($m),
2010–2018 65
Table 52: Generics in Coronary Artery Disease Market, Global, Annual Cost of Therapy ($),
2004–2010 66
Table 53: Generics in Coronary Artery Disease Market, Global, Annual Cost of Therapy ($),
2010–2018 66
Table 54: Generics in Coronary Artery Disease Market, Global, Treatment Usage Pattern (million),
2004–2010 67
Table 55: Generics in Coronary Artery Disease Market, Global, Treatment Usage Pattern (million),
2010–2018 67
Table 56: Generics in Angina Pectoris Market, Global, Revenue ($m), 2004–2010 71
Table 57: Generics in Angina Pectoris Market, Global, Revenue Forecasts ($m), 2010–2018 72
Table 58: Generics in Angina Pectoris Market, Global, Annual Cost of Therapy ($), 2004–2010 72
Table 59: Generics in Angina Pectoris Market, Global, Annual Cost of Therapy ($), 2010–2018 72
Table 60: Generics in Angina Pectoris Market, Global, Treatment Usage Pattern (million),
2004–2010 74
Table 61: Generics in Angina Pectoris Market, Global, Treatment Usage Pattern (million),
2010–2018 74

9. Table 62: Generics in Cardiovascular Diseases Market, Global, Research and Development
Pipeline by Phase in PAH, 2011 78
Table 63: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia, Regulatory and
Phase III Research and Development Pipeline, 2011 81
Table 64: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia, Phase II Research
and Development Pipeline, 2011 82
Table 65: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia, Phase I Research
and Development Pipeline, 2011 84
Table 66: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia, Pre-Clinical and
Discovery Research and Development Pipeline, 2011 85
Table 67: Generics in Cardiovascular Diseases Market, Global, Research and Development
Pipeline by Phase in CAD, 2011 88
Table 68: Generics in Cardiovascular Diseases Market, Global, Research and Development
Pipeline by Phase in Angina Pectoris, 2011 89
Table 69: Generics in Cardiovascular Diseases Market, Global, Research and Development
Pipeline by Phase in Thrombosis (%), 2011 90
Table 70: Generics in Cardiovascular Diseases Market, Global, Hypertension Regulatory Filing
and Phase III Research and Development Pipeline, 2011 92
Table 71: Generics in Cardiovascular Diseases Market, Global, Hypertension Phase II Research
and Development Pipeline, 2011 94
Table 72: Generics in Cardiovascular Diseases Market, Global, Hypertension Phase I Research
and Development Pipeline, 2011 95
Table 73: Generics in Cardiovascular Diseases Market, Global, Hypertension Pre-clinical and
Discovery Research and Development Pipeline, 2011 96
Table 74: Generics in Cardiovascular Diseases Market, Global, M&A Deals, 2010-2011 104
Table 75: Generics in Cardiovascular Diseases Market, Global, Licensing Deals, 2010–2011 111
1.2 List of Figures
Figure 1: Generics in Cardiovascular Diseases Market, Global, Revenue Forecasts ($bn),
2004–2018 16
Figure 2: Generics in Cardiovascular Diseases Market, Global, Annual Cost of Therapy($),
2004–2018 18
Figure 3: Generics in Cardiovascular Diseases Market, Global, Treatment Usage Patterns
(million), 2004–2018 19
Figure 4: Generics in Cardiovascular Diseases Market, The US, Revenue Forecasts ($bn),
2004–2018 21
Figure 5: Generics in Cardiovascular Diseases Market, The US, Annual Cost of Therapy($),
2004–2018 22
Figure 6: Generics in Cardiovascular Diseases Market, The US, Treatment Usage Patterns
(million), 2004–2018 24
Figure 7: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Revenue

10. Forecasts ($bn), 2004–2018 26
Figure 8: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Annual Cost
of Therapy($), 2004–2018 27
Figure 9: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Treatment
Usage Patterns (million), 2004–2018 28
Figure 10: Generics in Cardiovascular Diseases Market, Japan, Revenue Forecasts ($m),
2004–2018 30
Figure 11: Generics in Cardiovascular Diseases Market, Japan, Annual Cost of Therapy ($),
2004–2018 31
Figure 12: Generics in Cardiovascular Diseases Market, Japan, Treatment Usage Patterns
(million), 2004–2018 32
Figure 13: Generics in Thrombosis Market, Global, Revenue Forecasts ($m), 2004–2018 35
Figure 14: Generics in Thrombosis Market, Global, Annual Cost of Therapy ($), 2004–2018 36
Figure 15: Generics in Cardiovascular Diseases Market, Global, Thrombosis, Treatment Flow
Algorithm 37
Figure 16: Generics in Thrombosis Market, Global, Treatment Usage Pattern (million), 2004–2018
38
Figure 17: Generics in Thrombosis Market, Global, Drivers and Restraints, 2011 40
Figure 18: Generics in Pulmonary Arterial Hypertension Market, Global, Revenue Forecasts ($m),
2004–2018 43
Figure 19: Generics in Pulmonary Arterial Hypertension Market, Global, Annual Cost of Therapy
($), 2004–2018 44
Figure 20: Generics in Pulmonary Arterial Hypertension Market, Global, Treatment Usage
Patterns, (‘000), 2004–2018 46
Figure 21: Generics in Cardiovascular Diseases Market, Global, Pulmonary Arterial Hypertension,
Treatment Flow Algorithm, 2010 48
Figure 22: Generics in Pulmonary Arterial Hypertension, Global, Drivers and Restraints, 2011 48
Figure 23: Generics in Hypertension Market, Global, Revenue Forecasts ($bn), 2004–2018 51
Figure 24: Generics in Hypertension Market, Global, Annual Cost of Therapy ($), 2004–2018 52
Figure 25: Generics in Cardiovascular Diseases Market, Global, Hypertension, Treatment Flow
Algorithm, 2011 53
Figure 26: Generics in Hypertension Market, Global, Treatment Usage Pattern (million),
2004–2018 54
Figure 27: Generics in Hypertension Market, Global, Drivers and Restraints, 2010 56
Figure 28: Generics in Dyslipidemia Market, Global, Revenue Forecasts ($bn), 2004–2018 57
Figure 29: Generics in Dyslipidemia Market, Global, Annual Cost of Therapy ($), 2004–2018 59
Figure 30: Generics in Cardiovascular Diseases Market, Dyslipidemia, Treatment Flow Algorithm
60
Figure 31: Generics in Dyslipidemia Market, Global, Treatment Usage Pattern (million),
2004–2018 61
Figure 32: Generics in Dyslipidemia Market, Global, Drivers and Restraints, 2010 62

11. Figure 33: Generics in Coronary Artery Disease Market, Global, Revenue Forecasts ($m),
2004–2018 64
Figure 34: Generics in Coronary Artery Disease Market, Global, Annual Cost of Therapy ($),
2004–2018 66
Figure 35: Generics in Coronary Artery Disease Market, Global, Treatment Usage Pattern
(million), 2004–2018 67
Figure 36: Generics in Coronary Artery Disease Market, Global, Drivers and Restraints, 2011 69
Figure 37: Generics in Angina Pectoris Market, Global, Revenue Forecasts ($bn), 2004–2018 71
Figure 38: Generics in Angina Pectoris Market, Global, Annual Cost of Therapy ($), 2004–2018 72
Figure 39: Generics in Cardiovascular Diseases Market, Global, Angina Pectoris, Treatment Flow
Algorithm 73
Figure 40: Generics in Angina Pectoris Market, Global, Treatment Usage Pattern (million),
2004–2018 74
Figure 41: Generics in Angina Pectoris Market, Global, Drivers and Restraints, 2011 75
Figure 42: Generics in Cardiovascular Diseases Market, Global Product Pipeline by Indication (%),
2011 77
Figure 43: Generics in Cardiovascular Diseases Market, Global, Research and Development
Pipeline by Phase in PAH (%), 2011 78
Figure 44: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia Research and
Development Pipeline by Phase (%), 2011 81
Figure 45: Generics in Cardiovascular Diseases Market, Global, Research and Development
Pipeline by Phase in CAD (%), 2011 87
Figure 46: Generics in Cardiovascular Diseases Market, Global, Research and Development
Pipeline by Phase in Thrombosis (%), 2011 89
Figure 47: Generics in Cardiovascular Diseases Market, Global, Research and Development
Pipeline by Phase in Hypertension (%), 2011 92
Figure 48: Generics in Cardiovascular Diseases Market, Global, M&A Deals by Year, 2004–2011
106
Figure 49: Generics in Cardiovascular Diseases Market, Global, M&A Deals by Geography,
2004–2011 107
Figure 50: Generics in Cardiovascular Diseases Market, Global, M&A Deals by Value ($m),
2004–2010 108
Figure 51: Generics in Cardiovascular Diseases Market, Global, Licensing Deals by Indication (%),
2004–2011 113
Figure 52: Generics in Cardiovascular Diseases Market, Global, Licensing Deals by Geography
(%), 2004–2011 114
Figure 53: Generics in Cardiovascular Diseases Market, Global, Licensing Deals by Year,
2004–2011 115
Figure 54: Generics in Cardiovascular Diseases Market, Global, Co-development Deals by
Indication (%), 2004-2011 117
Figure 55: Generics in Cardiovascular Diseases Market, Global, Co-development Deals by

12. Geography (%), 2004–2010 118
Figure 56: Generics in Cardiovascular Diseases Market, Global, Co-development Deals by Year,
2004-2011 119
Figure 57: GBI Research Market Forecasting Model 128
Contact: sales@reportsandreports.com for more information.